Inside Eli Lilly’s Revenue Trends in 3Q17

A look at Eli Lilly

Eli Lilly (LLY) is a US-based multinational pharmaceutical company headquartered in Indianapolis. Its product portfolio includes human pharmaceuticals and animal health products. The company reported 9% YoY (year-over-year) growth in its top line to ~$5.7 billion for 3Q17.

Inside Eli Lilly’s Revenue Trends in 3Q17

Eli Lilly surpassed the Wall Street analysts’ 3Q17 revenue estimate of ~$5.5 billion as well as the EPS (earnings per share) estimate of $1.03, reporting $1.05 for the latest quarter.

Stock performance

LLY stock has risen ~10.1% over the past 12 months and 13.8% YTD (year-to-date). Its top-line increase was driven by the strong performance of human pharmaceuticals and animal health products. It reported net income of $1.1 billion for 3Q17, which was 19% higher YoY.

US markets contributed ~54.8% of LLY’s total revenues in 3Q17 at $3.1 billion, which was a 9% YoY rise, due to the increased sales of Basaglar, Jardiance, Lartruvo, Taltz, and Trulicity, and companion animal products including the acquired portfolio of US feline, canine, and rabies vaccines acquired from Boehringer Ingelheim.

The contribution from outside the US was ~45.1% of total 3Q17 revenues at ~$2.6 billion, which was 8% higher YoY and mainly driven by Humalog and Forteo sales.

Notably, the Health Care Select Sector SPDR ETF (XLV) has 2.6% of its total portfolio in Eli Lilly (LLY). XLV also has 1.9% in Allergan (AGN), 3.0% in Gilead Sciences (GILD), and 2.1% in Biogen (BIIB).